Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3020MR)

This product GTTS-WQ3020MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3020MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5249MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ5246MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ13336MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ13752MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ11439MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ5259MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ15919MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8508MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW